CSL Behring has signed a letter of intent with the pan‑Canadian Pharmaceutical Alliance to advance public reimbursement discussions for Hemgenix, the first gene therapy approved for hemophilia B. The agreement is an early step toward making the therapy more accessible across Canada’s public drug plans.
Read the full story here: https://finance.yahoo.com/news/csl-behring-signs-letter-intent-120000800.html
